Literature DB >> 10492738

Evaluation of the impact of Dublin's expanded harm reduction programme on prevalence of hepatitis C among short-term injecting drug users.

B P Smyth1, E Keenan, J J O'Connor.   

Abstract

Mesh：

Year:  1999        PMID： 10492738      PMCID： PMC1756924          DOI： 10.1136/jech.53.7.434

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN： 0143-005X            Impact factor:   3.710


× No keyword cloud information.
  5 in total

Review 1.  Once more unto the breach: controlling hepatitis C in injecting drug users.

Authors:  A Wodak; N Crofts
Journal:  Addiction       Date:  1996-02       Impact factor: 6.526

2.  Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses.

Authors:  R S Garfein; D Vlahov; N Galai; M C Doherty; K E Nelson
Journal:  Am J Public Health       Date:  1996-05       Impact factor: 9.308

3.  Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program.

Authors:  H Hagan; D C Jarlais; S R Friedman; D Purchase; M J Alter
Journal:  Am J Public Health       Date:  1995-11       Impact factor: 9.308

4.  Changes in the injecting risk behaviour of injecting drug users in London, 1990-1993.

Authors:  G M Hunter; M C Donoghoe; G V Stimson; T Rhodes; C P Chalmers
Journal:  AIDS       Date:  1995-05       Impact factor: 4.177

5.  Deaths, HIV infection, abstinence, and other outcomes in a cohort of injecting drug users followed up for 10 years.

Authors:  J R Robertson; P J Ronald; G M Raab; A J Ross; T Parpia
Journal:  BMJ       Date:  1994-08-06
  5 in total
  9 in total

1.  Bloodborne virus infections among drug users in Ireland: a retrospective cross-sectional survey of screening, prevalence, incidence and hepatitis B immunisation uptake.

Authors:  L Grogan; M Tiernan; N Geogeghan; B Smyth; E Keenan
Journal:  Ir J Med Sci       Date:  2005 Apr-Jun       Impact factor: 1.568

2.  Hepatitis C viral clearance in an intravenous drug-using cohort in the Dublin area.

Authors:  S Keating; S Coughlan; J Connell; B Sweeney; E Keenan
Journal:  Ir J Med Sci       Date:  2005 Jan-Mar       Impact factor: 1.568

3.  Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey.

Authors:  S Allwright; F Bradley; J Long; J Barry; L Thornton; J V Parry
Journal:  BMJ       Date:  2000-07-08

4.  Blood-borne infections in Dublin's opiate users.

Authors:  M Fitzgerald; J Barry; P O'Sullivan; L Thornton
Journal:  Ir J Med Sci       Date:  2001 Jan-Mar       Impact factor: 2.089

5.  A review of the evidence for the effectiveness of primary prevention interventions for hepatitis C among injecting drug users.

Authors:  Nat M J Wright; Charlotte N E Tompkins
Journal:  Harm Reduct J       Date:  2006-09-06

Review 6.  Hepatitis C virus infection in Irish drug users and prisoners - a scoping review.

Authors:  D Crowley; R Murtagh; W Cullen; J S Lambert; T McHugh; M C Van Hout
Journal:  BMC Infect Dis       Date:  2019-08-08       Impact factor: 3.090

Review 7.  Analysis of duration of risk behaviour for key populations: a literature review.

Authors:  Erika Fazito; Paloma Cuchi; Mary Mahy; Tim Brown
Journal:  Sex Transm Infect       Date:  2012-12       Impact factor: 3.519

8.  Opioid substitution treatment and heroin dependent adolescents: reductions in heroin use and treatment retention over twelve months.

Authors:  Bobby P Smyth; Khalifa Elmusharaf; Walter Cullen
Journal:  BMC Pediatr       Date:  2018-05-04       Impact factor: 2.125

9.  Incidence of hepatitis C among people who inject drugs in Ireland.

Authors:  Anne Marie Carew; Niamh Murphy; Jean Long; Kate Hunter; Suzi Lyons; Cathal Walsh; Lelia Thornton
Journal:  Hepatol Med Policy       Date:  2017-01-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.